OKYO Pharma Limited
OKYO
$2.42
$0.052.11%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 4.84M | 4.67M | 4.49M | 6.00M | 7.51M |
| Gross Profit | -4.84M | -4.67M | -4.49M | -6.00M | -7.51M |
| SG&A Expenses | -- | -- | -- | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.09M | 8.72M | 10.35M | 13.05M | 15.75M |
| Operating Income | -7.09M | -8.72M | -10.35M | -13.05M | -15.75M |
| Income Before Tax | -7.97M | -10.07M | -12.17M | -14.48M | -16.80M |
| Income Tax Expenses | -3.26M | -2.37M | -1.48M | -727.90K | 22.40K |
| Earnings from Continuing Operations | -4.71 | -7.70 | -10.69 | -13.76 | -16.83 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.71M | -7.70M | -10.69M | -13.76M | -16.83M |
| EBIT | -7.09M | -8.72M | -10.35M | -13.05M | -15.75M |
| EBITDA | -7.09M | -8.72M | -10.35M | -13.05M | -15.75M |
| EPS Basic | -0.12 | -0.22 | -0.32 | -0.45 | -0.59 |
| Normalized Basic EPS | -0.13 | -0.18 | -0.23 | -0.30 | -0.37 |
| EPS Diluted | -0.12 | -0.22 | -0.32 | -0.45 | -0.59 |
| Normalized Diluted EPS | -0.13 | -0.18 | -0.23 | -0.30 | -0.37 |
| Average Basic Shares Outstanding | 157.95M | 145.52M | 133.09M | 125.23M | 117.38M |
| Average Diluted Shares Outstanding | 157.95M | 145.52M | 133.09M | 125.23M | 117.38M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |